Health Returns to Pharmaceutical Innovation in the Market for Oral Chemotherapy in Response to Insurance Coverage Expansion
Author
Abstract
Suggested Citation
Download full text from publisher
As the access to this document is restricted, you may want to search for a different version of it.
References listed on IDEAS
- David H. Howard & Peter B. Bach & Ernst R. Berndt & Rena M. Conti, 2015. "Pricing in the Market for Anticancer Drugs," Journal of Economic Perspectives, American Economic Association, vol. 29(1), pages 139-162, Winter.
- Daron Acemoglu & Joshua Linn, 2004.
"Market Size in Innovation: Theory and Evidence from the Pharmaceutical Industry,"
The Quarterly Journal of Economics, Oxford University Press, vol. 119(3), pages 1049-1090.
- Daron Acemoglu & Joshua Linn, 2003. "Market Size in Innovation: Theory and Evidence From the Pharmaceutical Industry," NBER Working Papers 10038, National Bureau of Economic Research, Inc.
- Daron Acemoglu & Joshua Linn, 2004. "Market Size in Innovation: Theory and Evidence from the Pharmaceutical Industry," Levine's Working Paper Archive 228400000000000002, David K. Levine.
- Blume-Kohout, Margaret E. & Sood, Neeraj, 2013. "Market size and innovation: Effects of Medicare Part D on pharmaceutical research and development," Journal of Public Economics, Elsevier, vol. 97(C), pages 327-336.
- David H. Howard & Peter B. Bach & Ernst R. Berndt & Rena M. Conti, 2015. "Pricing in the Market for Anticancer Drugs," NBER Working Papers 20867, National Bureau of Economic Research, Inc.
- David Dranove & Craig Garthwaite & Manuel Hermosilla, 2014. "Pharmaceutical Profits and the Social Value of Innovation," NBER Working Papers 20212, National Bureau of Economic Research, Inc.
Most related items
These are the items that most often cite the same works as this one and are cited by the same works as this one.- David Besanko & David Dranove & Craig Garthwaite, 2016. "Insurance and the High Prices of Pharmaceuticals," NBER Working Papers 22353, National Bureau of Economic Research, Inc.
- Agarwal, Ruchir & Gaule, Patrick, 2022.
"What drives innovation? Lessons from COVID-19 R&D,"
Journal of Health Economics, Elsevier, vol. 82(C).
- Agarwal, Ruchir & Gaule, Patrick, 2021. "What Drives Innovation? Lessons from COVID-19 R&D," IZA Discussion Papers 14079, Institute of Labor Economics (IZA).
- Ruchir Agarwal & Patrick Gaulé, 2021. "What Drives Innovation? Lessons from COVID-19 R&D," IMF Working Papers 2021/048, International Monetary Fund.
- Jillian Chown & David Dranove & Craig Garthwaite & Jordan Keener, 2019. "The Opportunities and Limitations of Monopsony Power in Healthcare: Evidence from the United States and Canada," NBER Working Papers 26122, National Bureau of Economic Research, Inc.
- Hermosilla, Manuel & Wu, Yufei, 2018. "Market size and innovation: The intermediary role of technology licensing," Research Policy, Elsevier, vol. 47(5), pages 980-991.
- Dranove, David & Garthwaite, Craig & Heard, Christopher & Wu, Bingxiao, 2022.
"The economics of medical procedure innovation,"
Journal of Health Economics, Elsevier, vol. 81(C).
- David Dranove & Craig Garthwaite & Christopher Heard & Bingxiao Wu, 2021. "The Economics of Medical Procedure Innovation," NBER Working Papers 29438, National Bureau of Economic Research, Inc.
- David B. Ridley & Chung-Ying Lee, 2020. "Does Medicare Reimbursement Drive Up Drug Launch Prices?," The Review of Economics and Statistics, MIT Press, vol. 102(5), pages 980-993, December.
- Higgins, Matthew J. & Yan, Xin & Chatterjee, Chirantan, 2021. "Unpacking the effects of adverse regulatory events: Evidence from pharmaceutical relabeling," Research Policy, Elsevier, vol. 50(1).
- David Dranove & Craig Garthwaite & Manuel I. Hermosilla, 2020. "Expected Profits and The Scientific Novelty of Innovation," NBER Working Papers 27093, National Bureau of Economic Research, Inc.
- Gamba, Simona & Magazzini, Laura & Pertile, Paolo, 2021. "R&D and market size: Who benefits from orphan drug legislation?," Journal of Health Economics, Elsevier, vol. 80(C).
- Katharina E. Blankart & Frank R. Lichtenberg, 2022.
"The Effects of Off-label Drug Use on Disability and Medical Expenditure,"
NBER Working Papers
30440, National Bureau of Economic Research, Inc.
- Blankart, Katharina & Lichtenberg, Frank R., 2022. "The effects of off-label drug use on disability and medical expenditure," Ruhr Economic Papers 969, RWI - Leibniz-Institut für Wirtschaftsforschung, Ruhr-University Bochum, TU Dortmund University, University of Duisburg-Essen.
- Nicholas Bagley & Benjamin Berger & Amitabh Chandra & Craig Garthwaite & Ariel D. Stern, 2018. "The Orphan Drug Act at 35: Observations and an Outlook for the Twenty-First Century," NBER Chapters, in: Innovation Policy and the Economy, Volume 19, pages 97-137, National Bureau of Economic Research, Inc.
- Colleen Carey, 2017. "Technological Change and Risk Adjustment: Benefit Design Incentives in Medicare Part D," American Economic Journal: Economic Policy, American Economic Association, vol. 9(1), pages 38-73, February.
- Edouard Debonneuil & Anne Eyraud-Loisel & Frédéric Planchet, 2018.
"Can Pension Funds Partially Manage Longevity Risk by Investing in a Longevity Megafund?,"
Risks, MDPI, vol. 6(3), pages 1-27, July.
- Edouard Debonneuil & Anne Eyraud-Loisel & Frédéric Planchet, 2018. "Can Pension Funds Partially Manage Longevity Risk by Investing in a Longevity Megafund?," Post-Print hal-01571937, HAL.
- Giammario Impullitti & Richard Kneller & Danny McGowan, 2020.
"Demand‐Driven Technical Change and Productivity Growth: Theory and Evidence FROM the Energy Policy Act,"
Journal of Industrial Economics, Wiley Blackwell, vol. 68(2), pages 328-363, June.
- Giammario Impullitti & Richard Kneller & Danny McGowan, 2017. "Demand-driven Technical Change and Productivity Growth: Theory and Evidence from the US Energy Policy Act," Discussion Papers 2017/03, University of Nottingham, Centre for Finance, Credit and Macroeconomics (CFCM).
- Heidi L. Williams, 2016.
"Intellectual Property Rights and Innovation: Evidence from Health Care Markets,"
Innovation Policy and the Economy, University of Chicago Press, vol. 16(1), pages 53-87.
- Heidi L. Williams, 2015. "Intellectual Property Rights and Innovation: Evidence from Health Care Markets," NBER Chapters, in: Innovation Policy and the Economy, Volume 16, pages 53-87, National Bureau of Economic Research, Inc.
- Heidi L. Williams, 2015. "Intellectual Property Rights and Innovation: Evidence from Health Care Markets," NBER Working Papers 21246, National Bureau of Economic Research, Inc.
- Salas-Vega, Sebastian & Shearer, Emily & Mossialos, Elias, 2020. "Relationship between costs and clinical benefits of new cancer medicines in Australia, France, the UK, and the US," Social Science & Medicine, Elsevier, vol. 258(C).
- Matthew T. Knowles, 2022. "How access to addictive drugs affects the supply of substance abuse treatment: Evidence from Medicare Part D," Health Economics, John Wiley & Sons, Ltd., vol. 31(8), pages 1649-1675, August.
- Fabian Gaessler & Stefan Wagner, 2022.
"Patents, Data Exclusivity, and the Development of New Drugs,"
The Review of Economics and Statistics, MIT Press, vol. 104(3), pages 571-586, May.
- Gaessler, Fabian & Wagner, Stefan, 2019. "Patents, Data Exclusivity, and the Development of New Drugs," Rationality and Competition Discussion Paper Series 176, CRC TRR 190 Rationality and Competition.
- Mark Pauly & Kyle Myers, 2016. "A Ricardian-Demand Explanation for Changing Pharmaceutical R&D Productivity," NBER Working Papers 22720, National Bureau of Economic Research, Inc.
- Sabine Vogler & Valérie Paris & Alessandra Ferrario & Veronika J. Wirtz & Kees Joncheere & Peter Schneider & Hanne Bak Pedersen & Guillaume Dedet & Zaheer-Ud-Din Babar, 2017. "How Can Pricing and Reimbursement Policies Improve Affordable Access to Medicines? Lessons Learned from European Countries," Applied Health Economics and Health Policy, Springer, vol. 15(3), pages 307-321, June.
More about this item
Keywords
pharmaceutical innovation; chemotherapy; Part D;All these keywords.
JEL classification:
- I11 - Health, Education, and Welfare - - Health - - - Analysis of Health Care Markets
- I13 - Health, Education, and Welfare - - Health - - - Health Insurance, Public and Private
- I18 - Health, Education, and Welfare - - Health - - - Government Policy; Regulation; Public Health
Statistics
Access and download statisticsCorrections
All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:tpr:amjhec:v:5:y:2019:i:3:p:360-375. See general information about how to correct material in RePEc.
If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.
If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .
If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.
For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Kelly McDougall (email available below). General contact details of provider: https://direct.mit.edu/journals .
Please note that corrections may take a couple of weeks to filter through the various RePEc services.